Tasked with exploring the molecular basis of drug-side effects, InnoMed PredTox is an ambitious project involving leading European pharmaceutical companies, academic research institutes and Genedata.
The gathering in Dublin met for an update on general progress over the last nine months and to discuss the consortium’s newly launched central data sharing portal. Biomolecular data from more than 20 laboratories is fed into a joint database, which is based on Genedata’s Expressionist platform.
Researchers use the portal via a secure Internet connection and have begun to share data and experimental design information. “The portal is critical for the management of the project’s progress”, said Dr. Laura Suter-Dick, Section Head for New Technologies in Safety, Roche.
Progress has been rapid, especially considering that the project involves cooperation between 20 independent research organizations. Earlier this year, members of the consortium met for an intensive planning session at Genedata’s headquarters in Basel. They agreed on critical design aspects of the database and on a sophisticated data analysis plan.
The InnoMed PredTox collaboration with Genedata is laying the foundation for toxicology to exploit genome-wide biological data in drug development. Genechip microarrays, 2D-gel and mass spectromerty experimental data is combined with conventional toxicology findings and clinical chemistry data. “Genedata is proud of the central place it occupies in InnoMed’s computational activities”, explained Dr. Othmar Pfannes, CEO of Genedata.
The InnoMed PredTox Second General Assembly was hosted by the Conway Institute (UCD), Dublin, Ireland, October 10th-11th, 2006. The InnoMed PredTox project is supported by partial funding under the Sixt Research Framework Programme of the European Union (LSHB-CT-2005-518170).
tobe freeman | alfa
Lethal combination: Drug cocktail turns off the juice to cancer cells
12.12.2018 | Universität Basel
Smelling the forest – not the trees
12.12.2018 | Universität Konstanz
A widely used diabetes medication combined with an antihypertensive drug specifically inhibits tumor growth – this was discovered by researchers from the University of Basel’s Biozentrum two years ago. In a follow-up study, recently published in “Cell Reports”, the scientists report that this drug cocktail induces cancer cell death by switching off their energy supply.
The widely used anti-diabetes drug metformin not only reduces blood sugar but also has an anti-cancer effect. However, the metformin dose commonly used in the...
A research team from the University of Zurich has developed a new drone that can retract its propeller arms in flight and make itself small to fit through narrow gaps and holes. This is particularly useful when searching for victims of natural disasters.
Inspecting a damaged building after an earthquake or during a fire is exactly the kind of job that human rescuers would like drones to do for them. A flying...
Over the last decade, there has been much excitement about the discovery, recognised by the Nobel Prize in Physics only two years ago, that there are two types...
What if a sensor sensing a thing could be part of the thing itself? Rice University engineers believe they have a two-dimensional solution to do just that.
Rice engineers led by materials scientists Pulickel Ajayan and Jun Lou have developed a method to make atom-flat sensors that seamlessly integrate with devices...
Scientists at the University of Stuttgart and the Karlsruhe Institute of Technology (KIT) succeed in important further development on the way to quantum Computers.
Quantum computers one day should be able to solve certain computing problems much faster than a classical computer. One of the most promising approaches is...
10.12.2018 | Event News
06.12.2018 | Event News
03.12.2018 | Event News
12.12.2018 | Life Sciences
12.12.2018 | Life Sciences
12.12.2018 | Health and Medicine